Friday, December 02, 2005 1:55:43 AM
Forbes.com, David Ng, 11.28.05, 2:26 PM ET
Piper Jaffray reiterated an "outperform" rating and $43 target price on Amylin Pharmaceuticals (nasdaq: AMLN - news - people ), saying the company's diabetes treatments still have the upper hand over the competing product from Novo Nordisk (nyse: NVO - news - people ).
"We believe that Amylin will continue to hold multiple competitive advantages with its Byetta franchise, including more convenient dosing frequency, timeline and first mover advantage," Piper analyst Thomas Wei wrote in a note to investors.
Novo Nordisk's liraglutide has shown "impressive" results for phase IIb trials, according to Piper. The research firm added that liraglutide has reached "the gold standard measure" for glycemic control.
"On safety, the drug appeared well tolerated, with a low 5% to 10% rate of nausea and no hypoglycemia reported," Piper said.
Novo Nordisk recently reiterated its intent to initiate a 3,800-patient, Phase III program in February 2006, according to the research firm.
Piper believes Amylin can obtain regulatory approval for its long-acting release exenatide treatment with a much smaller patient database, thus potentially beating Novo Nordisk to market.
http://www.forbes.com/markets/2005/11/28/amylin-pharmaceuticals-novo-1128markets08.html?partner=yaho...
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM